

Novartis Pharmaceuticals Corporation

Novartis Pharmaceuticals Corporation

Novartis

- [Novartis 2024 11 11](#)

Novartis Pharmaceuticals Corporation

- [Novartis 2024 11 11](#)

Novartis Pharmaceuticals Corporation

- [2024 11 11](#)

Novartis Pharmaceuticals Corporation

- [12.5mg Novartis Pharmaceuticals Corporation](#)
- [12.5mg \(Novartis Pharmaceuticals Corporation\)](#)
- [25mg Novartis Pharmaceuticals Corporation](#)
- [25mg \(Novartis Pharmaceuticals Corporation\)](#)

Novartis Pharmaceuticals Corporation

- [12.5](#)
- [25](#)
- [12.5mg PTP Novartis Pharmaceuticals Corporation 1](#)
- [25mg PTP Novartis Pharmaceuticals Corporation 1](#)
- [12.5mg PTP Novartis Pharmaceuticals Corporation 7](#)
- [25mg PTP Novartis Pharmaceuticals Corporation 7](#)

12.5mg Novartis Pharmaceuticals Corporation 2021 12 11 25mg Novartis Pharmaceuticals Corporation 2021 12 11

Novartis Pharmaceuticals Corporation

- [Novartis Pharmaceuticals Corporation 2018 2](#)
- [Novartis Pharmaceuticals Corporation 2020 4](#)
- [Novartis Pharmaceuticals Corporation 2021 10](#)
- [Novartis Pharmaceuticals Corporation 2023 5](#)

Novartis Pharmaceuticals Corporation

- [\[REDACTED\]2024\[REDACTED\]11\[REDACTED\]](#)

[REDACTED]

[REDACTED]

[\[REDACTED\(ITP\)\]_CETB115B1401_\[REDACTED\]_20220627](#)

[REDACTED]

[CETB115E1402_8th_PSR_20221212](#)

[REDACTED](RMP)

- [\[REDACTED\]](#)

[REDACTED]

- [EXTEND\[REDACTED\]](#)
[Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study.](#)
- [\[REDACTED\]12.5mg 70\[REDACTED\]PTP\[REDACTED\]](#)

[REDACTED]

[\[REDACTED\]](#)

Source URL: <https://loadtest.pro.novartis.com/products/revolade/document>